Qinlock (ripretinib) is indicated to treat adult patients with advanced gastrointestinal stromal tumors (GIST).
The drug from Qinlock won FDA approval on May 15, 2020.
In the Phase 3 INVICTUS study, the drug demonstrated clinical benefits with dose escalation for patients with advanced gastrointestinal stromal tumors with disease progression.
The pharma and biotech editor of WTWH Media, Brian is a veteran journalist with more than 15 years of experience covering an array of life science topics, including clinical trials, drug discovery and development and medical devices. Before coming to WTWH, he served as content director focused on connected devices at Informa. In addition, Brian covered the medical device sector for 10 years at UBM. At Qmed, he overhauled the brand’s news coverage and helped to grow the site’s traffic volume dramatically. He had previously held managing editor roles on two of the company’s medical device technology publications. Connect with him on LinkedIn or email at [email protected]
Tell Us What You Think!
You must be logged in to post a comment.